Details of the Drug

General Information of Drug (ID: DMWXLYZ)

Drug Name
Darifenacin
Synonyms
Enablex; Emselex; 133099-04-4; UNII-APG9819VLM; UK-88525; APG9819VLM; CHEMBL1346; CHEBI:391960; (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; darifenacine; [3H]darifenacin; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide; NCGC00168775-01; Darifenacin (USAN/INN); Darifenacinum; Darifenacina; Darifenacin [USAN:INN:BAN]; Emselex; Emselex (TN); Enablex (TN)
Indication
Disease Entry ICD 11 Status REF
Overactive bladder GC50.0 Approved [1], [2], [3]
Therapeutic Class
Urinary antispasmodics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 426.5
Topological Polar Surface Area (xlogp) 4.6
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 15% [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 12 mL/min/kg [6]
Elimination
12.5% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 13 - 19 hours [6]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.41379 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [6]
Vd
The volume of distribution (Vd) of drug is 163 L [8]
Chemical Identifiers
Formula
C28H30N2O2
IUPAC Name
2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide
Canonical SMILES
C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5
InChI
InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1
InChIKey
HXGBXQDTNZMWGS-RUZDIDTESA-N
Cross-matching ID
PubChem CID
444031
ChEBI ID
CHEBI:391960
CAS Number
133099-04-4
DrugBank ID
DB00496
TTD ID
D0Y5AM
INTEDE ID
DR0417
ACDINA ID
D00169

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor (CHRM) TTOXS3C NOUNIPROTAC Antagonist [9]
Muscarinic acetylcholine receptor M3 (CHRM3) TTQ13Z5 ACM3_HUMAN Antagonist [10], [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Overactive bladder
ICD Disease Classification GC50.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Muscarinic acetylcholine receptor M3 (CHRM3) DTT CHRM3 4.61E-07 -0.59 -0.73
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Darifenacin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Darifenacin and Solifenacin. Functional bladder disorder [GC50] [49]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Darifenacin and Tolterodine. Functional bladder disorder [GC50] [49]
Coadministration of a Drug Treating the Disease Different from Darifenacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Bethanechol DMCLHO0 Moderate Antagonize the effect of Darifenacin when combined with Bethanechol. Abnormal micturition [MF50] [50]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Darifenacin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [51]
Arn-509 DMT81LZ Moderate Increased metabolism of Darifenacin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [51]
Oliceridine DM6MDCF Major Decreased metabolism of Darifenacin caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [52]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Darifenacin and Scopolamine. Addictive disorder [6C50-6C5Z] [49]
Mitotane DMU1GX0 Moderate Increased metabolism of Darifenacin caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [51]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Darifenacin and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [53]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Darifenacin and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [53]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Darifenacin and Memantine. Alzheimer disease [8A20] [49]
Galantamine DMEO794 Moderate Antagonize the effect of Darifenacin when combined with Galantamine. Alzheimer disease [8A20] [54]
Rivastigmine DMG629M Moderate Antagonize the effect of Darifenacin when combined with Rivastigmine. Alzheimer disease [8A20] [54]
Donepezil DMIYG7Z Moderate Antagonize the effect of Darifenacin when combined with Donepezil. Alzheimer disease [8A20] [54]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Darifenacin caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [51]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Darifenacin caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [55]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Darifenacin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [49]
Voriconazole DMAOL2S Major Decreased metabolism of Darifenacin caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [56]
Posaconazole DMUL5EW Major Decreased metabolism of Darifenacin caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [56]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Darifenacin caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [51]
Desipramine DMT2FDC Moderate Decreased metabolism of Darifenacin caused by Desipramine mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [51]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Darifenacin caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [51]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Darifenacin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [57]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Darifenacin caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [51]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Darifenacin and Loperamide. Bowel habit change [ME05] [58]
Tucatinib DMBESUA Major Decreased metabolism of Darifenacin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [56]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Darifenacin when combined with Acetylcholine. Cataract [9B10] [59]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Darifenacin and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [60]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Darifenacin and Tiotropium. Chronic obstructive pulmonary disease [CA22] [60]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Darifenacin and Revefenacin. Chronic obstructive pulmonary disease [CA22] [60]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Darifenacin caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [51]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Darifenacin and Dihydrocodeine. Chronic pain [MG30] [61]
Alfentanil DMVO0UB Moderate Additive antimotility effects by the combination of Darifenacin and Alfentanil. Corneal disease [9A76-9A78] [62]
Dextromethorphan DMUDJZM Moderate Decreased metabolism of Darifenacin caused by Dextromethorphan mediated inhibition of CYP450 enzyme. Cough [MD12] [56]
Mifepristone DMGZQEF Major Decreased metabolism of Darifenacin caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [56]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Darifenacin caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [51]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Darifenacin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [51]
MK-8228 DMOB58Q Moderate Decreased metabolism of Darifenacin caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [51]
Aprepitant DM053KT Moderate Decreased metabolism of Darifenacin caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Sertraline DM0FB1J Moderate Decreased metabolism of Darifenacin caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Darifenacin and Cyclobenzaprine. Depression [6A70-6A7Z] [49]
Nortriptyline DM4KDYJ Moderate Decreased metabolism of Darifenacin caused by Nortriptyline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Nefazodone DM4ZS8M Major Decreased metabolism of Darifenacin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [56]
Paroxetine DM5PVQE Moderate Decreased metabolism of Darifenacin caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Escitalopram DMFK9HG Moderate Decreased metabolism of Darifenacin caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
OPC-34712 DMHG57U Major Decreased metabolism of Darifenacin caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [63]
Clomipramine DMINRKW Moderate Decreased metabolism of Darifenacin caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Amoxapine DMKITQE Moderate Decreased metabolism of Darifenacin caused by Amoxapine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Doxepin DMPI98T Moderate Decreased metabolism of Darifenacin caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Maprotiline DMPWB7T Moderate Decreased metabolism of Darifenacin caused by Maprotiline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Nitroglycerin DMQ2491 Minor Decreased dissolution of Darifenacin taken sublingually caused by Nitroglycerin. Diabetic foot ulcer [BD54] [64]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Darifenacin and Mepenzolate. Digestive system disease [DE2Z] [49]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Darifenacin and Oxybutynine. Discovery agent [N.A.] [49]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Darifenacin and Meclizine. Dizziness and giddiness [MB48] [49]
Fenfluramine DM0762O Moderate Decreased metabolism of Darifenacin caused by Fenfluramine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Darifenacin and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [65]
Primidone DM0WX6I Moderate Increased metabolism of Darifenacin caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Felbamate DM1V5ZS Moderate Increased metabolism of Darifenacin caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Darifenacin caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Cenobamate DMGOVHA Moderate Increased metabolism of Darifenacin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Darifenacin caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Phenobarbital DMXZOCG Moderate Increased metabolism of Darifenacin caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Carbamazepine DMZOLBI Moderate Increased metabolism of Darifenacin caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Darifenacin caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Darifenacin and Diphenhydramine. Episodic vestibular syndrome [AB31] [49]
Benzthiazide DMQWZ0H Minor Altered absorption of Darifenacin due to GI dynamics variation caused by Benzthiazide. Essential hypertension [BA00] [66]
Tazemetostat DMWP1BH Moderate Increased metabolism of Darifenacin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [51]
Itraconazole DMCR1MV Major Decreased metabolism of Darifenacin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [56]
Terbinafine DMI6HUW Moderate Decreased metabolism of Darifenacin caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [51]
Miconazole DMPMYE8 Moderate Decreased metabolism of Darifenacin caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [51]
Ketoconazole DMPZI3Q Major Decreased metabolism of Darifenacin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [56]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Darifenacin and Propantheline. Gastric ulcer [DA60] [49]
Cimetidine DMH61ZB Moderate Decreased metabolism of Darifenacin caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [51]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Darifenacin when combined with Isoflurophate. Glaucoma [9C61] [59]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Darifenacin when combined with Pilocarpine. Glaucoma [9C61] [50]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Darifenacin caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [51]
Carvedilol DMHTEAO Moderate Decreased metabolism of Darifenacin caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [51]
Chlorothiazide DMLHESP Minor Altered absorption of Darifenacin due to GI dynamics variation caused by Chlorothiazide. Heart failure [BD10-BD1Z] [66]
Hydroflumethiazide DMVPUQI Minor Altered absorption of Darifenacin due to GI dynamics variation caused by Hydroflumethiazide. Heart failure [BD10-BD1Z] [66]
Boceprevir DMBSHMF Major Decreased metabolism of Darifenacin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [56]
Telaprevir DMMRV29 Major Decreased metabolism of Darifenacin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [56]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Darifenacin caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [51]
Rifampin DMA8J1G Moderate Increased metabolism of Darifenacin caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [55]
Rifapentine DMCHV4I Moderate Increased metabolism of Darifenacin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [51]
Delavirdine DM3NF5G Major Decreased metabolism of Darifenacin caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Darifenacin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Cobicistat DM6L4H2 Major Decreased metabolism of Darifenacin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Efavirenz DMC0GSJ Moderate Increased metabolism of Darifenacin caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Saquinavir DMG814N Major Decreased metabolism of Darifenacin caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Etravirine DMGV8QU Moderate Increased metabolism of Darifenacin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Amprenavir DMLMXE0 Major Decreased metabolism of Darifenacin caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Darunavir DMN3GCH Moderate Decreased metabolism of Darifenacin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Atazanavir DMSYRBX Major Decreased metabolism of Darifenacin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Ritonavir DMU764S Major Decreased metabolism of Darifenacin caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [56]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Darifenacin caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [51]
Levamlodipine DM92S6N Moderate Decreased metabolism of Darifenacin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [51]
Verapamil DMA7PEW Moderate Decreased metabolism of Darifenacin caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [51]
Pindolol DMD2NV7 Moderate Decreased metabolism of Darifenacin caused by Pindolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [51]
Indapamide DMGN1PW Minor Altered absorption of Darifenacin due to GI dynamics variation caused by Indapamide. Hypertension [BA00-BA04] [66]
Trichlormethiazide DMHAQCO Minor Altered absorption of Darifenacin due to GI dynamics variation caused by Trichlormethiazide. Hypertension [BA00-BA04] [66]
Hydrochlorothiazide DMUSZHD Minor Altered absorption of Darifenacin due to GI dynamics variation caused by Hydrochlorothiazide. Hypertension [BA00-BA04] [66]
Potassium chloride DMMTAJC Major Increased risk of GI mucosal injury/bleeding risk by the combination of Darifenacin and Potassium chloride. Hypo-kalaemia [5C77] [68]
Conivaptan DM1V329 Major Decreased metabolism of Darifenacin caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [56]
Givosiran DM5PFIJ Moderate Decreased metabolism of Darifenacin caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [51]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Darifenacin and Belladonna. Infectious gastroenteritis/colitis [1A40] [49]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Darifenacin and Amantadine. Influenza [1E30-1E32] [69]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Darifenacin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [70]
Amobarbital DM0GQ8N Moderate Increased metabolism of Darifenacin caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [51]
Propiomazine DMKY8V1 Moderate Decreased metabolism of Darifenacin caused by Propiomazine mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [51]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Darifenacin and ITI-007. Insomnia [7A00-7A0Z] [49]
R0-93877 DMM4U9G Moderate Antagonize the effect of Darifenacin when combined with R0-93877. Irritable bowel syndrome [DD91] [71]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Darifenacin and Clidinium. Irritable bowel syndrome [DD91] [49]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Darifenacin and Dicyclomine. Irritable bowel syndrome [DD91] [49]
Physostigmine DM2N0TO Moderate Antagonize the effect of Darifenacin when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [54]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Darifenacin caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [51]
Crizotinib DM4F29C Moderate Decreased metabolism of Darifenacin caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [51]
Ceritinib DMB920Z Major Decreased metabolism of Darifenacin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [56]
PF-06463922 DMKM7EW Moderate Increased metabolism of Darifenacin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [51]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Darifenacin caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [51]
Selpercatinib DMZR15V Moderate Decreased metabolism of Darifenacin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [51]
Lumefantrine DM29GAD Moderate Decreased metabolism of Darifenacin caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [57]
Halofantrine DMOMK1V Moderate Decreased metabolism of Darifenacin caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [51]
Chloroquine DMSI5CB Moderate Decreased metabolism of Darifenacin caused by Chloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [51]
Primaquine DMWQ16I Moderate Decreased metabolism of Darifenacin caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [51]
Idelalisib DM602WT Major Decreased metabolism of Darifenacin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [56]
IPI-145 DMWA24P Moderate Decreased metabolism of Darifenacin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [51]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Darifenacin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [57]
Danazol DML8KTN Moderate Decreased metabolism of Darifenacin caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [51]
Exjade DMHPRWG Moderate Increased metabolism of Darifenacin caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [51]
Panobinostat DM58WKG Moderate Decreased metabolism of Darifenacin caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [51]
Neostigmine DM6T2J3 Moderate Antagonize the effect of Darifenacin when combined with Neostigmine. Myasthenia gravis [8C6Y] [72]
Pyridostigmine DM8HO1L Moderate Antagonize the effect of Darifenacin when combined with Pyridostigmine. Myasthenia gravis [8C6Y] [72]
Edrophonium DMCRQHB Moderate Antagonize the effect of Darifenacin when combined with Edrophonium. Myasthenia gravis [8C6Y] [72]
Ambenonium DMOP0BL Moderate Antagonize the effect of Darifenacin when combined with Ambenonium. Myasthenia gravis [8C6Y] [72]
Rifabutin DM1YBHK Moderate Increased metabolism of Darifenacin caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [51]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Darifenacin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [51]
Nilotinib DM7HXWT Moderate Decreased metabolism of Darifenacin caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [51]
Dasatinib DMJV2EK Moderate Decreased metabolism of Darifenacin caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [51]
Modafinil DMYILBE Minor Increased metabolism of Darifenacin caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [73]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Darifenacin and Dimenhydrinate. Nausea/vomiting [MD90] [49]
Promethazine DM6I5GR Moderate Decreased metabolism of Darifenacin caused by Promethazine mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [51]
Rolapitant DM8XP26 Moderate Decreased metabolism of Darifenacin caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [74]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Darifenacin and Cyclizine. Nausea/vomiting [MD90] [49]
Netupitant DMEKAYI Moderate Decreased metabolism of Darifenacin caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [57]
Metoclopramide DMFA5MY Moderate Decreased metabolism of Darifenacin caused by Metoclopramide mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [51]
Bupropion DM5PCS7 Moderate Decreased metabolism of Darifenacin caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [51]
Entrectinib DMMPTLH Moderate Decreased metabolism of Darifenacin caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [51]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Darifenacin caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [51]
Dexfenfluramine DMJ7YDS Moderate Decreased metabolism of Darifenacin caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [51]
Metolazone DMB39LO Minor Altered absorption of Darifenacin due to GI dynamics variation caused by Metolazone. Oedema [MG29] [66]
Polythiazide DMCH80F Minor Altered absorption of Darifenacin due to GI dynamics variation caused by Polythiazide. Oedema [MG29] [66]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Darifenacin and Levomethadyl Acetate. Opioid use disorder [6C43] [61]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Darifenacin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [51]
Pentazocine DM1XBHS Moderate Additive antimotility effects by the combination of Darifenacin and Pentazocine. Pain [MG30-MG3Z] [62]
Dextropropoxyphene DM23HCX Moderate Additive CNS depression effects by the combination of Darifenacin and Dextropropoxyphene. Pain [MG30-MG3Z] [61]
Butorphanol DM5KYPJ Moderate Additive antimotility effects by the combination of Darifenacin and Butorphanol. Pain [MG30-MG3Z] [62]
Oxymorphone DM65AGJ Moderate Additive antimotility effects by the combination of Darifenacin and Oxymorphone. Pain [MG30-MG3Z] [62]
Levorphanol DMGS80V Moderate Additive antimotility effects by the combination of Darifenacin and Levorphanol. Pain [MG30-MG3Z] [62]
Dezocine DMJDB0Y Moderate Additive antimotility effects by the combination of Darifenacin and Dezocine. Pain [MG30-MG3Z] [62]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Darifenacin and Flavoxate. Pain [MG30-MG3Z] [49]
Nalbuphine DMOSQGU Moderate Additive antimotility effects by the combination of Darifenacin and Nalbuphine. Pain [MG30-MG3Z] [62]
Methamphetamine DMPM4SK Moderate Decreased metabolism of Darifenacin caused by Methamphetamine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [75]
Buprenorphine DMPRI8G Moderate Additive antimotility effects by the combination of Darifenacin and Buprenorphine. Pain [MG30-MG3Z] [62]
Hydrocodone DMQ2JO5 Moderate Additive antimotility effects by the combination of Darifenacin and Hydrocodone. Pain [MG30-MG3Z] [62]
Oxycodone DMXLKHV Moderate Additive antimotility effects by the combination of Darifenacin and Oxycodone. Pain [MG30-MG3Z] [62]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Darifenacin and Biperiden. Parkinsonism [8A00] [49]
Levodopa DMN3E57 Moderate Altered absorption of Darifenacin due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [76]
Abametapir DM2RX0I Moderate Decreased metabolism of Darifenacin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [77]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Darifenacin and Methylscopolamine. Peptic ulcer [DA61] [49]
Lefamulin DME6G97 Moderate Decreased metabolism of Darifenacin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [78]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Darifenacin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [56]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Darifenacin caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [51]
Enzalutamide DMGL19D Moderate Increased metabolism of Darifenacin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [51]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Darifenacin caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [51]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Darifenacin caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [79]
Levomepromazine DMIKFEL Moderate Decreased metabolism of Darifenacin caused by Levomepromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [51]
Fluphenazine DMIT8LX Moderate Decreased metabolism of Darifenacin caused by Fluphenazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [51]
Triflupromazine DMKFQJP Moderate Decreased metabolism of Darifenacin caused by Triflupromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [51]
Bosentan DMIOGBU Moderate Increased metabolism of Darifenacin caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [51]
Dexamethasone DMMWZET Moderate Increased metabolism of Darifenacin caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [51]
Nafcillin DMN9RPO Moderate Increased metabolism of Darifenacin caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [51]
Oxamniquine DM2QDX1 Moderate Decreased metabolism of Darifenacin caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [51]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Darifenacin and Quetiapine. Schizophrenia [6A20] [49]
Mesoridazine DM2ZGAN Moderate Decreased metabolism of Darifenacin caused by Mesoridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [51]
Thioridazine DM35M8J Major Decreased metabolism of Darifenacin caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [80]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Darifenacin caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [51]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Darifenacin and Iloperidone. Schizophrenia [6A20] [49]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Darifenacin and Paliperidone. Schizophrenia [6A20] [49]
Haloperidol DM96SE0 Moderate Decreased metabolism of Darifenacin caused by Haloperidol mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [51]
Molindone DMAH70G Moderate Decreased metabolism of Darifenacin caused by Molindone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [51]
Thiothixene DMDINC4 Moderate Decreased metabolism of Darifenacin caused by Thiothixene mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [51]
Trifluoperazine DMKBYWI Moderate Decreased metabolism of Darifenacin caused by Trifluoperazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [51]
Risperidone DMN6DXL Moderate Decreased metabolism of Darifenacin caused by Risperidone mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [51]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Darifenacin and Asenapine. Schizophrenia [6A20] [49]
Pimozide DMW83TP Major Decreased metabolism of Darifenacin caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [81]
Fentanyl DM8WAHT Moderate Additive antimotility effects by the combination of Darifenacin and Fentanyl. Sensation disturbance [MB40] [62]
Sufentanil DMU7YEL Moderate Additive antimotility effects by the combination of Darifenacin and Sufentanil. Sensation disturbance [MB40] [62]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Darifenacin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [51]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Darifenacin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [57]
Larotrectinib DM26CQR Moderate Decreased metabolism of Darifenacin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [51]
Armodafinil DMGB035 Minor Increased metabolism of Darifenacin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [73]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Darifenacin caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [57]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Darifenacin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [82]
Pramlintide DM0EZ9Q Moderate Altered absorption of Darifenacin due to GI dynamics variation caused by Pramlintide. Type-1/2 diabete [5A10-5A11] [83]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Darifenacin and Atropine. Unspecific substance harmful effect [NE6Z] [49]
Nitrofurantoin DM7PQIK Minor Altered absorption of Darifenacin due to GI dynamics variation caused by Nitrofurantoin. Urinary tract infection [GC08] [84]
Elagolix DMB2C0E Moderate Increased metabolism of Darifenacin caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [51]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Darifenacin and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [49]
Methdilazine DMAUHQX Moderate Decreased metabolism of Darifenacin caused by Methdilazine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [51]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Darifenacin and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [49]
Trimeprazine DMEMV9D Moderate Decreased metabolism of Darifenacin caused by Trimeprazine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [57]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Darifenacin and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [49]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Darifenacin and Acrivastine. Vasomotor/allergic rhinitis [CA08] [49]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Darifenacin and Azatadine. Vasomotor/allergic rhinitis [CA08] [49]
Propafenone DMPIBJK Moderate Decreased metabolism of Darifenacin caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [51]
Flecainide DMSQDLE Moderate Decreased metabolism of Darifenacin caused by Flecainide mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [51]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Darifenacin caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [51]
⏷ Show the Full List of 215 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Quinoline yellow WS E00309 24671 Colorant
Sunset yellow FCF E00255 17730 Colorant
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 200 E00648 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 19 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Darifenacin 7.5 mg tablet 7.5 mg 24 HR Extended Release Oral Tablet Oral
Darifenacin 15 mg tablet 15 mg 24 HR Extended Release Tablet Oral
Darifenacin 15 mg tablet 15 mg 24 HR Extended Release Oral Tablet Oral
Darifenacin 7.5 mg tablet 7.5 mg 24 HR Extended Release Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 321).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
4 BDDCS applied to over 900 drugs
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9 Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84.
10 M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5.
11 The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
25 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
26 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
27 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
29 Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66.
30 Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70.
31 Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35.
32 Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7.
33 Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs. Nihon Yakurigaku Zasshi. 1999 Mar;113(3):157-66.
34 Clinical pipeline report, company report or official report of GlaxoSmithKline.
35 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
36 The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63.
37 Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7.
38 Long-acting bronchodilators in COPD: Where are we now and where are we going Breathe 06/2014; 10(2):110-120.
39 Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
40 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
41 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
42 Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69.
43 Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62.
44 Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
45 Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6.
46 Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94.
47 Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123.
48 Agonist-regulated alteration of the affinity of pancreatic muscarinic cholinergic receptors. J Biol Chem. 1993 Oct 25;268(30):22436-43.
49 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
50 Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
51 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
52 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
53 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
54 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
55 Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748]
56 Cerner Multum, Inc. "Australian Product Information.".
57 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
58 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
59 Multum Information Services, Inc. Expert Review Panel.
60 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
61 Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
62 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
63 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
64 Product Information. Nitrostat (nitroglycerin). Parke-Davis, Morris Plains, NJ.
65 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
66 Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
67 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
68 Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
69 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
70 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
71 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
72 Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
73 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
74 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
75 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
76 Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
77 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
78 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
79 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
80 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
81 Canadian Pharmacists Association.
82 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
83 Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.
84 Jaffe JM "Effect of propantheline on nitrofurantoin absorption." J Pharm Sci 64 (1975): 1729-30. [PMID: 1185550]